5Y6:FRA
Compass Pathways PLC
€۷٫۲۰
arrow_upward
+۱٫۴۱%(+۰٫۱۰۰) ر
۱۰ اردیبهشت, ۹:۵۵:۰۱ (+۲ گرینویچ) · EUR
search
همه نمادها
ر
ر
م
م
سال تاکنون
۱ سال
y
حداکثر ۳۰
| نماد | قیمت | تغییر | تغییر |
|---|
insights_autoدرحال تولید اطلاعات آماری برتر برای 5Y6…
باز کردن
€۷٫۲۰
زیاد
€۷٫۲۰
کم
€۷٫۲۰
ارزش بازار
۱٫۱۳ میلیارد
میانگین حجم
۶۴۸٫۰۰
میزان صدا
۰٫۰۰
بیشترین در ۵۲ هفته
€۸٫۶۰
کمترین در ۵۲ هفته
€۲٫۱۰
[=1]تعداد کارمندان
۱۵۶
اخبار و داستان
از منابعی در وب
Barchart.com
·
۱ روز پیش
Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?
Yahoo Finance
·
۳ روز پیش
FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment
نمایه
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
درباره Compass Pathways PLC
محتوای هوش مصنوعی ممکن است اشتباهاتی داشته باشد.. بیشتر بدانید